In a report released yesterday, Naureen Quibria from Maxim Group maintained a Buy rating on Immutep, with a price target of $8.00. The company’s shares closed last Wednesday at $3.84.
According to TipRanks.com, Quibria is a 2-star analyst with an average return of
Immutep has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
Aethlon Medical (AEMD)
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Aethlon Medical, with a price target of $9.00. The company’s shares closed last Wednesday at $2.88, close to its 52-week low of $1.43.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aethlon Medical with a $10.00 average price target, representing a 239.0% upside. In a report issued on November 10, Maxim Group also reiterated a Buy rating on the stock with a $11.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IMMP:
- Kraft Heinz Falls after Top Shareholder Offers to Sell Shares
- Anthem (ANTM) Receives a Hold from Mizuho Securities
- Nvidia Q3 Results Beat Estimates; Issues Guidance
- Leerink Partners Keeps Their Buy Rating on Molecular Partners (MOLN)
- Evercore ISI Reaffirms Their Buy Rating on Codiak BioSciences (CDAK)